Clinical Trials Logo

SARS-CoV-2 Serological Status clinical trials

View clinical trials related to SARS-CoV-2 Serological Status.

Filter by:
  • None
  • Page 1

NCT ID: NCT04441684 Completed - Clinical trials for SARS-CoV-2 Seroprevalence

Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)

SeroCoV-HUS
Start date: April 17, 2020
Phase: N/A
Study type: Interventional

COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden increase of patients with COVID-19 resulted from a SARS-CoV-2 superspreading event (religious meeting). Infected individuals went to regional hospitals, and this led to a cluster of infected healthcare workers at the Strasbourg University Hospitals from the first week of March. To date, several hundred Strasbourg hospital workers have presented a SARS-CoV-2 infection confirmed by the RT-PCR test from a nasopharyngeal sample. Most of them developed a mild form of COVID-19. It is important to understand how far the infection has spread in the hospital staff, and to which extent the individuals who have been infected develop antibodies against SARS-CoV-2.